Bayer offers $2.4bn for Xofigo partner Algeta
This article was originally published in Scrip
Bayer has made a $2.4bn offer for Algeta, its Norwegian partner for the prostate cancer drug Xofigo (radium-223 dichloride). The preliminary offer represents a 27% premium to Algeta's closing share price on the Oslo stock exchange on 25 November before the bid was made public.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.